Donepezil Hydrochloride
Product Images NDC 71335-0876

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 71335-0876). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 11 (Donepezil Figur11)

A line graph displaying the SIB change from baseline (LS mean ± SE) over 24 weeks of drug treatment for Donepezil hydrochloride at 10 mg/day and 23 mg/day. The chart shows clinical improvement or decline over time, comparing the two dosages across several weeks.*

FDA Label Image

Figure 12 (Donepezil Figur12)

A cumulative percentage plot showing the patient response to Donepezil Hydrochloride at doses of 10 mg/day and 23 mg/day. The x-axis represents SIB (Severe Impairment Battery) change from baseline, while the y-axis shows the cumulative percentage of patients. Two curves compare the treatment effects of the two dosage levels over a range of SIB changes.*

FDA Label Image

Figure 13 (Donepezil Figur13)

A bar chart comparing the percentage of patients according to CIBIC-plus rating categories for Donepezil hydrochloride at 23 mg/day and 10 mg/day doses. Categories include Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse, with corresponding patient percentages on the vertical axis.*

FDA Label Image

Figure 1 (Donepezil Figure1)

A line graph showing the time-course of change from baseline in ADAS-cog scores over 24 weeks of drug treatment. The graph compares Donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo groups in patients, illustrating clinical improvement and decline over time with means and error bars.*

FDA Label Image

Figure 10 (Donepezil Figure10)

A cumulative percentage plot showing the change from baseline in ADCS-ADL scores over 6 months for patients treated with Donepezil Hydrochloride 10 mg/day compared to placebo. The x-axis represents change from baseline, and the y-axis shows cumulative percentage of patients completing the study.*

FDA Label Image

Figure 2 (Donepezil Figure2)

A cumulative percentage line graph showing the change in ADAS-cog scores from baseline for patients treated with Donepezil Hydrochloride 5 mg, 10 mg, and placebo over 24 weeks. The x-axis represents change from baseline, and the y-axis shows cumulative percentage of patients. The graph includes lines for placebo, 5 mg, and 10 mg doses with markers at 7 points, 4 points, and no change, alongside a table summarizing percentage changes in three treatment groups.*

FDA Label Image

Figure 3 (Donepezil Figure3)

A bar chart showing the frequency distribution of CIBIC plus scores at Week 24 for patients taking Donepezil hydrochloride 10 mg/day, Donepezil hydrochloride 5 mg/day, and placebo. The x-axis lists improvement categories from markedly improved to markedly worse, and the y-axis represents the percentage of patients in each category.*

FDA Label Image

Figure 4 (Donepezil Figure4)

A line graph depicting the time-course change from baseline in ADAS-cog scores over 15 weeks for donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The y-axis shows the mean change from baseline with standard error bars, and the x-axis shows weeks of drug treatment. Donepezil groups show clinical improvement compared to placebo.*

FDA Label Image

Figure 5 (Donepezil Figure5)

A cumulative percentage graph showing patients with specified changes from baseline ADAS-cog scores in a study comparing placebo, Donepezil Hydrochloride 5 mg, and Donepezil Hydrochloride 10 mg treatment groups. The x-axis represents change from baseline, while the y-axis shows cumulative percentage of patients. Markers indicate points of 7, 4, and no change along the x-axis, with an inset table summarizing percentage changes for each treatment group.*

FDA Label Image

Figure 6 (Donepezil Figure6)

A bar chart showing the frequency distribution of CIBIC-plus scores at Week 12 for patients taking donepezil hydrochloride 10 mg/day, 5 mg/day, and placebo. The x-axis lists patient improvement categories from markedly improved to markedly worse, and the y-axis shows the percentage of patients. Data bars represent patient response percentages across the three groups for each category.*

FDA Label Image

Figure 7 (Donepezil Figure7)

A line graph depicting the time course of change from baseline in SIB score over 6 months of drug treatment for Donepezil Hydrochloride 10 mg/day versus placebo. The y-axis represents SIB change from baseline with clinical improvement or decline indicated, and the x-axis shows months of treatment. Donepezil shows an increase in SIB score, while placebo shows a decrease.*

FDA Label Image

Figure 8 (Donepezil Figure8)

A cumulative percentage graph showing patient response to Donepezil Hydrochloride 10 mg/day compared to placebo. The x-axis measures change in SIB scores from baseline, with negative values indicating improvement. The y-axis shows the cumulative percentage of patients completing six months of double-blind treatment. Donepezil exhibits a higher cumulative percentage of patients with improvement than placebo.*

FDA Label Image

Structure (Donepezil Structure)

Chemical structure of Donepezil Hydrochloride, showing its molecular arrangement including aromatic rings, methoxy groups, and a piperidine ring bound to a hydrochloride ion.*

FDA Label Image

Label Image (Lbl713350876)

Donepezil 5mg Tablet label from Bryant Ranch Prepack for 90 tablets. The label notes the product is comparable to Aricept 5mg Tablet by Alembic Pharmaceuticals Limited. It includes storage instructions to keep at room temperature of 20°-25°C (68°-77°F) and shows the NDC number 71335-0876 with a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.